drugset / Trial / NCT01969656

Safety Study of an Oral Vitamin D Analog in Postmenopausal Women

NCT01969656

Phase 1 Completed Deltanoid Pharmaceuticals

Summary

Determine the safety of 2MD, a vitamin D analog, when administered orally once daily for 28 days in healthy normal postmenopausal women.

Timeline

Start
Primary completion
2004-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcitriol Small molecule
Subject DP001 Small molecule 50 ng Oral
Subject DP001 Small molecule 110 ng Oral
Subject DP001 Small molecule 170 ng Oral
Subject DP001 Small molecule 220 ng Oral
Subject DP001 Small molecule 440 ng Oral